The use of artificial intelligence is widespread across life sciences organisations but its use in drug research and development is limited, analysis finds. 

Research by The Pistoia Alliance, a not-for-profit life sciences advocacy group, shows 30% of life sciences professionals say their organisation has implemented an enterprise-wide AI platform, yet 69% lack clear metrics to assess AI’s impact on reducing the cost or time required for drug R&D. Just 4% report tangible benefits of AI for R&D leadership. 

The survey also revealed that AI’s impact is uneven throughout the R&D lifecycle. More than half (54%) of respondents said teams focused on regulatory submissions and reporting are seeing the greatest benefits from AI, alongside research analysis teams (21%). By contrast, just 13% cited value in automating scientific workflows and experiments, while only 1% report value in the wet lab. 

The poll, sponsored by Thoughtworks, was conducted at an event attended by 300 industry leaders at the Royal Society of Medicine in London. 

“A key focus at this year’s conference was understanding why the gap between AI investment and value persists,” said Dr Becky Upton, President of The Pistoia Alliance. 

“The polls show AI success depends on getting both the data and people elements right – 59% say their companies need to prioritise data quality and accessibility, while 22% highlight AI adoption and change management. 

“The success stories shared on stage show these barriers can be overcome by combining technology, scientific and regulatory expertise. In essence, progress depends on collaboration, which is where the Alliance plays a critical role, bringing organisations together through a portfolio of projects and communities that continues to evolve in line with industry needs.”